Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Pacific Biosciences of California, Inc. reported revenue of $160M, up 3.9% year over year. Operating margin was -346.2% and net margin -341.5%, on a free-cash-flow margin of -71.2% with capital expenditure at 1.7% of revenue. Every figure is computed directly from PACB's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $160M | -346.2% | -341.5% |
| FY2024 | $154M | -308.0% | -201.2% |
| FY2023 | $201M | -166.8% | -153.0% |
| FY2022 | $128M | -239.4% | -244.9% |
| FY2021 | $131M | -161.2% | -138.9% |
How does PACB compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.